Evidence of KA21.pdf

download Evidence of KA21.pdf

of 36

Transcript of Evidence of KA21.pdf

  • 8/17/2019 Evidence of KA21.pdf

    1/36

    Evidence of KA21

  • 8/17/2019 Evidence of KA21.pdf

    2/36

    Antitumor beta glucan from the cultured fruit body of Agaric

    http://www.ncbi.nlm.nih.gov/pubmed/11456124 

    http://www.ncbi.nlm.nih.gov/pubmed/11456124http://www.ncbi.nlm.nih.gov/pubmed/11456124

  • 8/17/2019 Evidence of KA21.pdf

    3/36

    Antitumor activity

  • 8/17/2019 Evidence of KA21.pdf

    4/36

    Ipomoea batatas and Agarics blazei ameliorate diabetic disordtherapeutic antioxidant potential in streptozotocin-induced drats.

    http://www.ncbi.nlm.nih.gov/pubmed/21562638 

    http://www.ncbi.nlm.nih.gov/pubmed/21562638http://www.ncbi.nlm.nih.gov/pubmed/21562638

  • 8/17/2019 Evidence of KA21.pdf

    5/36

    Diabetes

    Blood sugar

    normal

    control

    Ipomoea bata

    Kingagaricus

    Week

  • 8/17/2019 Evidence of KA21.pdf

    6/36

    Immunomodulating Activity of Agaricus brasiliensis KA21 in MHuman Volunteers.

    http://www.ncbi.nlm.nih.gov/pubmed/18604247 

    http://www.ncbi.nlm.nih.gov/pubmed/18604247http://www.ncbi.nlm.nih.gov/pubmed/18604247

  • 8/17/2019 Evidence of KA21.pdf

    7/36

    Biochemical

     parameters

    Before (mean ± SD) After (mean ± SD) Statistics ( P -valu

    Total protein (g dl – 1) 7.50 ± 0.16 7.41 ± 0.25 0.31

    BUN (mg dl – 1) 15.81± 5.93 13.45± 2.25 0.12

    Creatinine (mg dl – 1) 0.92 ± 0.21 0.90 ± 0.20 0.19

    GOT (µ l – 1) 18.8 ± 4.75 19.8 ± 4.40 0.10

    GPT (µ l – 1) 15.7 ± 6.90 16.3 ± 4.90 0.52

    -GTP (µ l – 1) 35.4 ± 29.6GTP 35.9 ± 30.1 0.89

    (N  = 11).

    Table 3. Safety of A. brasi l iensis  KA21 in human volunteers

    Kingagaricus100 9g a day was administrated for 6 months to 11 subjects

    Safety data

  • 8/17/2019 Evidence of KA21.pdf

    8/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on body weight

    The normal dose was administrated to 12 subjects for 3 months

  • 8/17/2019 Evidence of KA21.pdf

    9/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on BMI

    The normal dose was administrated to 12 subjects for 3 months

  • 8/17/2019 Evidence of KA21.pdf

    10/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on percentage body fat

    The normal dose was administrated to 12 subjects for 3 months

  • 8/17/2019 Evidence of KA21.pdf

    11/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on percentage visceral fat

    The normal dose was administrated to 12 subjects for 3 months

  • 8/17/2019 Evidence of KA21.pdf

    12/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on blood glucose level

    The normal dose was administrated to 12 subjects for 3 months

  • 8/17/2019 Evidence of KA21.pdf

    13/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on blood cholesterol level from the viewpoint of Mibyou

  • 8/17/2019 Evidence of KA21.pdf

    14/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Effect of A. brasiliensis on neutral fat level from the viewpoint of Mibyou

  • 8/17/2019 Evidence of KA21.pdf

    15/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Comparison of NK cell activity before and after administration of A. brasiliensis

    The normal dose or placebo was administrated to 8 subjects for 7 days (

  • 8/17/2019 Evidence of KA21.pdf

    16/36

    Copyright restrictions may apply.

    Liu, Y. et al. eCAM 2007 0:nem016v1-15; doi:10.1093/ecam/nem016

    Comparison of NK cell activity before and after administration of placebo

    The normal dose or placebo was administrated to 8 subjects for 7 days (

  • 8/17/2019 Evidence of KA21.pdf

    17/36

    Agaricus brasiliensis KA21 improves circulatory functions inspontaneously hypertensive rats.

    http://www.ncbi.nlm.nih.gov/pubmed/24433071 

    http://www.ncbi.nlm.nih.gov/pubmed/24433071http://www.ncbi.nlm.nih.gov/pubmed/24433071

  • 8/17/2019 Evidence of KA21.pdf

    18/36

    Improve Circulatory Function  (SHR)

  • 8/17/2019 Evidence of KA21.pdf

    19/36

    Diet

  • 8/17/2019 Evidence of KA21.pdf

    20/36

    Neutral Fat (Triglyceride)

  • 8/17/2019 Evidence of KA21.pdf

    21/36

    Protect Heart FunctionCentral Nerve system

    He

    Muscle

  • 8/17/2019 Evidence of KA21.pdf

    22/36

    Differences in antioxidant activities of outdoor- and indoor-cuAgaricus brasiliensis, and protective effects against carbontetrachloride-induced acute hepatic injury in mice.

    http://www.ncbi.nlm.nih.gov/pubmed/25418207 

    http://www.ncbi.nlm.nih.gov/pubmed/25418207http://www.ncbi.nlm.nih.gov/pubmed/25418207

  • 8/17/2019 Evidence of KA21.pdf

    23/36

    Antioxidant activity

    Kingagaricus Green house

  • 8/17/2019 Evidence of KA21.pdf

    24/36

    Liver Protection

    Normal

    Kingagaricus 3%

    Green house agaricus 3%

    10

  • 8/17/2019 Evidence of KA21.pdf

    25/36

    Liver Protection

    Normal

    Kingagaricus 10%

    24hours

  • 8/17/2019 Evidence of KA21.pdf

    26/36

    Open-Label Study of the Influence of Food Containing the RoyMushroom, Agaricus brasiliensis KA21 (Higher BasidiomyceteQuality of Life of Healthy Human Volunteers.

    http://www.ncbi.nlm.nih.gov/pubmed/26756293 

    http://www.ncbi.nlm.nih.gov/pubmed/26756293http://www.ncbi.nlm.nih.gov/pubmed/26756293

  • 8/17/2019 Evidence of KA21.pdf

    27/36

    QOL

    2.0

    2.2

    2.4

    2.6

    2.8

    3.0

    3.2

    3.4

    3.6

    3.8

    4.0

    Pre-intake 6th week 12th week

    Fatigue

    L H

    2.0

    2.2

    2.4

    2.6

    2.8

    3.0

    3.2

    3.4

    3.6

    3.8

    4.0

    Pre-intake 6th week 12th week

    Hair Loss

    L H

    2.0

    2.2

    2.4

    2.6

    2.8

    3.0

    3.2

    3.4

    3.6

    3.84.0

    Pre-intake 6th w

    Grey H

    L

    900mg or 1500mg

  • 8/17/2019 Evidence of KA21.pdf

    28/36

  • 8/17/2019 Evidence of KA21.pdf

    29/36

    QOL

    0.0

    0.2

    0.4

    0.6

    0.8

    1.0

    1.2

    1.4

    1.6

    1.8

    2.0

    Pre-intake 6th week 12th week

    difficulty staying awake during the day

    L H

    0.0

    0.2

    0.4

    0.6

    0.8

    1.0

    1.2

    1.4

    1.6

    1.8

    2.0

    Pre-intake 6th week

    ease of getting out of bed

    L H

  • 8/17/2019 Evidence of KA21.pdf

    30/36

    Not published data

    IGF 1

  • 8/17/2019 Evidence of KA21.pdf

    31/36

    IGF-1

    IGF-1 level High

    Low

    Peak

    Aging

  • 8/17/2019 Evidence of KA21.pdf

    32/36

    IGF-1

    • Anti-Aging effects

    Hair regrowth

    Improve immunity

    Better skin condition, less spots, wrinkles

    Improve cognitive function

    Improve metabolic syndrome

    Generative function

  • 8/17/2019 Evidence of KA21.pdf

    33/36

    IGF-1

    This is not K

    Anti-Aging

  • 8/17/2019 Evidence of KA21.pdf

    34/36

    0

    50

    100

    150

    200

    Control(n=5)

    Agalicus blazei(water extract) (10 mg/kg/day,

    po)(n=5)

    *, p

  • 8/17/2019 Evidence of KA21.pdf

    35/36

    IGF-1

    2 months

    Dog took Kingagaricus100 for 2 months

  • 8/17/2019 Evidence of KA21.pdf

    36/36

    Reduce side effect from anti cancer dru

    Number of Leucocyte

    Control

    cyclophosphamide; CPA

    cyclophosphamide; CPA+agaricus hot

    cyclophosphamide; CPA+agaricus cold